Literature DB >> 8135751

Transcriptional regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron.

O Alcantara1, S V Reddy, G D Roodman, D H Boldt.   

Abstract

Tartrate-resistant acid phosphatase (TRAP) was first identified in cells from patients with hairy cell leukaemia. Subsequently, it has been found in other leukaemias, B-lymphoblastoid cell lines, osteoclasts and subsets of normal lymphocytes, macrophages, and granulocytes. Recent data indicate that TRAP and porcine uteroferrin, a placental iron-transport protein, represent a single gene product. However, the intracellular role of TRAP is unknown. We used a full-length human placental TRAP cDNA probe to examine TRAP expression in human peripheral mononuclear cells (PMCs). TRAP mRNA increased 50-75-fold after 24 h in unstimulated PMC cultures. Cell-fractionation experiments indicated that monocytes were the main cell population accounting for increased TRAP mRNA transcripts, and this was confirmed by histochemical staining for TRAP enzyme activity. Because expression of other iron-binding and -transport proteins is controlled by iron availability, we examined the role of iron in regulating TRAP expression. Increase of TRAP mRNA transcripts in PMCs was inhibited by 50 microM desferrioxamine, a potent iron chelator. The 5' flanking region of the TRAP gene was cloned from a mouse genomic library. In preliminary transient transfection experiments, it was determined that the 5'-flanking region of the TRAP gene contained iron-responsive elements. Therefore, a series of stably transfected HRE H9 cell lines was developed bearing genetic constructs containing various segments of the murine TRAP 5' promoter region driving a luciferase reporter gene. Treatment of transfectants with 100 micrograms/ml iron-saturated human transferrin (FeTF) was performed to assess iron responsiveness of the constructs. Constructs containing a full-length TRAP promoter (comprising base pairs -1846 to +2) responded to FeTF with a 4-5-fold increase of luciferase activity whereas constructs containing only base pairs -363 to +2 of the TRAP promoter did not respond. Constructs containing 1240 or 881 bp of the TRAP promoter gave only a 1.5- to 2-fold increase of luciferase activity with FeTF. In all cases, increase of luciferase activity was blocked by desferrioxamine. Cells transfected with another luciferase construct driven by a simian virus 40 promoter did not show any increase of luciferase activity with FeTF. These data indicate that expression of TRAP is regulated by iron and that this regulation is exerted at the level of gene transcription. The transfection experiments also suggest that the region of the TRAP 5'-flanking sequence between base pairs -1846 and -1240 contains an iron regulatory element.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135751      PMCID: PMC1137957          DOI: 10.1042/bj2980421

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways.

Authors:  L Coussens; P J Parker; L Rhee; T L Yang-Feng; E Chen; M D Waterfield; U Francke; A Ullrich
Journal:  Science       Date:  1986-08-22       Impact factor: 47.728

Review 2.  Clinical significance of the human acid phosphatases: a review.

Authors:  L T Yam
Journal:  Am J Med       Date:  1974-05       Impact factor: 4.965

3.  Biochemical properties of human prostatic acid phosphatase.

Authors:  K W Lam; O Li; C Y Li; L T Yam
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

4.  Studies of two subpopulations of human lymphocytes differing in responsiveness to concanavalin A.

Authors:  S Boldt; A M Skinner; S Kornfeld
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

5.  Uteroferrin and intracellular tartrate-resistant acid phosphatases are the products of the same gene.

Authors:  P Ling; R M Roberts
Journal:  J Biol Chem       Date:  1993-04-05       Impact factor: 5.157

6.  A tartrate-resistant acid phosphatase from Gaucher spleen. Purification and properties.

Authors:  D B Robinson; R H Glew
Journal:  J Biol Chem       Date:  1980-06-25       Impact factor: 5.157

7.  Tartrate-resistant acid phosphatase staining of monocytes in Gaucher disease.

Authors:  K Troy; J Cuttner; M Reilly; G Grabowski; R Desnick
Journal:  Am J Hematol       Date:  1985-07       Impact factor: 10.047

8.  Cloning and characterization of the 5'-flanking region of the mouse tartrate-resistant acid phosphatase gene.

Authors:  S V Reddy; T Scarcez; J J Windle; R J Leach; J E Hundley; J M Chirgwin; J Y Chou; G D Roodman
Journal:  J Bone Miner Res       Date:  1993-10       Impact factor: 6.741

9.  The type 5, acid phosphatase from spleen of humans with hairy cell leukemia. Purification, properties, immunological characterization, and comparison with porcine uteroferrin.

Authors:  C M Ketcham; G A Baumbach; F W Bazer; R M Roberts
Journal:  J Biol Chem       Date:  1985-05-10       Impact factor: 5.157

10.  Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells. I. Tartrate-resistant acid phosphatase isoenzyme.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  Cancer       Date:  1986-05-01       Impact factor: 6.860

View more
  11 in total

1.  Expression patterns of purple acid phosphatase genes in Arabidopsis organs and functional analysis of AtPAP23 predominantly transcribed in flower.

Authors:  Huifen Zhu; Weiqiang Qian; Xuzhong Lu; Dongping Li; Xin Liu; Kunfan Liu; Daowen Wang
Journal:  Plant Mol Biol       Date:  2005-11       Impact factor: 4.076

Review 2.  Air pollutants disrupt iron homeostasis to impact oxidant generation, biological effects, and tissue injury.

Authors:  Andrew J Ghio; Joleen M Soukup; Lisa A Dailey; Michael C Madden
Journal:  Free Radic Biol Med       Date:  2020-02-21       Impact factor: 7.376

3.  Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.

Authors:  S Takahashi; S Goldring; M Katz; S Hilsenbeck; R Williams; G D Roodman
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

4.  Complex regulation of tartrate-resistant acid phosphatase (TRAP) expression by interleukin 4 (IL-4): IL-4 indirectly suppresses receptor activator of NF-kappaB ligand (RANKL)-mediated TRAP expression but modestly induces its expression directly.

Authors:  Minjun Yu; Jose L Moreno; Joseph P Stains; Achsah D Keegan
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

5.  Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice.

Authors:  Xing Shen; Chao Wan; Girish Ramaswamy; Mahendra Mavalli; Ying Wang; Craig L Duvall; Lian Fu Deng; Robert E Guldberg; Alan Eberhart; Thomas L Clemens; Shawn R Gilbert
Journal:  J Orthop Res       Date:  2009-10       Impact factor: 3.494

Review 6.  Desferoxamine (DFO)--mediated iron chelation: rationale for a novel approach to therapy for brain cancer.

Authors:  Pouya N Dayani; Maria C Bishop; Keith Black; Paul M Zeltzer
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

Review 7.  Clinical Impact and Cellular Mechanisms of Iron Overload-Associated Bone Loss.

Authors:  Viktória Jeney
Journal:  Front Pharmacol       Date:  2017-02-21       Impact factor: 5.810

Review 8.  Genes Critical for Developing Periodontitis: Lessons from Mouse Models.

Authors:  Teun J de Vries; Stefano Andreotta; Bruno G Loos; Elena A Nicu
Journal:  Front Immunol       Date:  2017-10-27       Impact factor: 7.561

9.  Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.

Authors:  Haye H van der Wal; Niels Grote Beverborg; Kenneth Dickstein; Stefan D Anker; Chim C Lang; Leong L Ng; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer
Journal:  Eur Heart J       Date:  2019-11-21       Impact factor: 29.983

Review 10.  Influence of Iron on Bone Homeostasis.

Authors:  Enikő Balogh; György Paragh; Viktória Jeney
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.